Stock Movers Novo Rebounds, Greggs Drops, UniCredit Pays Out
Feb 9, 2026
Louise Moon, Bloomberg breaking news editor who covers market-moving company news. She walks through Novo Nordisk’s rebound after a copycat pill was pulled. She covers Hims & Hers’ stock fallout and Jefferies’ downgrade of Greggs tied to weight-loss drugs. She also explains UniCredit’s plan to return about €50 billion and lift profitability.
AI Snips
Chapters
Transcript
Episode notes
Copycat Pull Boosts Novo Nordisk
- Novo Nordisk's shares rebounded after Hims & Hers pulled a copycat of Wegovy.
- The removal and FDA scrutiny reduce short-term imitation risk for Novo's key weight-loss pill.
Wegovy Is Central To Novo's Recovery
- Novo is depending on its new weight-loss pill for a recovery amid competition and political pressure.
- Market sensitivity to imitation and regulation makes the pill central to Novo's stock outlook.
Weight-Loss Drugs Pressure Greggs
- Jefferies cut Greggs to hold, citing weight-loss drugs as a structural headwind.
- Analysts expect reduced visits from higher-BMI frequent customers to weigh on Greggs' sales growth.